Patents Assigned to Aerpio Pharmaceuticals, Inc.
  • Humanized monoclonal antibodies that target VE-PTP (HPTP-?)
    Patent number: 11136389
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: October 5, 2021
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Methods of treating intraocular pressure with activators of Tie-2
    Patent number: 10952992
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 23, 2021
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventor: Kevin Gene Peters
  • Multispecific antibodies that target HPTP-? (VE-PTP) and VEGF
    Patent number: 10894824
    Abstract: The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: January 19, 2021
    Assignee: Aerpio Pharmaceuticals, Inc.
    Inventor: Kevin Peters
  • HPTP-Beta inhibitors
    Patent number: 10858354
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 8, 2020
    Assignee: Aerpio Pharmaceuticals, Inc.
    Inventors: John Janusz, James Copp, Kevin Peters
  • Methods for treating vascular leak syndrome and cancer
    Patent number: 10815300
    Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: October 27, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Robert Shalwitz
  • Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-?/VE-PTP)
    Patent number: 10604569
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 31, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
    Patent number: 10597452
    Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 24, 2020
    Assignee: AERPIO PHARMACEUTICALS, INC.
    Inventors: Kevin Peters, Michael Allen Flynn
  • Human protein tyrosine phosphatase inhibitors and methods of use
    Patent number: 10463650
    Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 5, 2019
    Assignee: Aerpio Pharmaceuticals, Inc.
    Inventors: Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier